Novartis has expanded its late-stage haematology pipeline with the acquisition of US-based Selexys Pharmaceuticals in a deal potentially worth US$665 M. The purchase comes 4 years after Novartis obtained an exclusive option to acquire Selexys following the successful completion of a Phase II clinical study of the company’s lead asset SelG1, an anti-P-selectin antibody, in patients with sickle cell disease.